Miyamura T, Kanda T, Nakamura M, Jiang X, Wu S, Nakamoto S, Mikami S, Takada N, Imazeki F, Yokosuka O. IL-28B polymorphisms and treatment response in hepatitis C virus patients with persistently normal alanine aminotransferase. World J Hepatol 2013; 5(11): 635-641 [PMID: 24303092 DOI: 10.4254/wjh.v5.i11.635]
Corresponding Author of This Article
Tatsuo Kanda, MD, PhD, Associate Professor, Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8677, Japan. firstname.lastname@example.org
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Tatsuo Miyamura, Tatsuo Kanda, Masato Nakamura, Xia Jiang, Shuang Wu, Shingo Nakamoto, Osamu Yokosuka, Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, Chiba 260-8677, Japan
Shigeru Mikami, Department of Internal Medicine, Kikkoman General Hospital, Noda 278-0005, Japan
Nobuo Takada, Department of Internal Medicine, Toho University, Sakura Medical Centre, Sakura 285-8741, Japan
Fumio Imazeki, Safety and Health Organization, Chiba University, Chiba 263-8522, Japan
Author contributions: Miyamura T and Kanda T designed the study and performed the majority of experiments; Kanda T, Mikami S, Takada N, Imazeki F and Yokosuka O collected all human samples; Miyamura T, Kanda T, Nakamura M, Jiang X and Wu S analyzed the data; Kanda T drafted the manuscript; all authors approved the manuscript.
Supported by Grants for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology, Japan; and Grants from the Ministry of Health, Labour and Welfare of Japan
Correspondence to: Tatsuo Kanda, MD, PhD, Associate Professor, Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8677, Japan. email@example.com
Telephone: +81-43-2262086 Fax: +81-43-2262088
Received: September 1, 2013 Revised: October 7, 2013 Accepted: November 2, 2013 Published online: November 27, 2013
Core tip: Whether the interleukin 28B (IL-28B) genotype affects the treatment response to peginterferon plus ribavirin in hepatitis C virus (HCV)-infected patients with persistently normal alanine aminotransferase (PNALT) is unclear. We examined the association between the IL-28B genotype and treatment response in HCV-infected patients with PNALT. Opinions about the appropriate treatment method for HCV-infected patients with PNALT differ. In the present study, we found that IL-28B rs8099917 TT was associated with SVR in HCV genotype 1-infected Asian patients with PNALT. The determination of IL-28B genotype is important for the successful treatment of HCV genotype 1-infected patients with PNALT.